Deutsche Bank set a €70.00 ($83.33) price objective on Stratec Biomedical Systems (ETR:SBS) in a research report released on Wednesday. The firm currently has a neutral rating on the stock.
Separately, Warburg Research set a €62.00 ($73.81) price objective on Stratec Biomedical Systems and gave the stock a neutral rating in a research report on Thursday, April 19th. Five investment analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Stratec Biomedical Systems currently has an average rating of Hold and an average target price of €62.83 ($74.80).
Get Stratec Biomedical Systems alerts:
Shares of SBS stock opened at €74.00 ($88.10) on Wednesday. Stratec Biomedical Systems has a twelve month low of €48.97 ($58.30) and a twelve month high of €75.00 ($89.29).
About Stratec Biomedical Systems
STRATEC Biomedical AG designs and manufactures solutions for automated processes in the fields of in vitro diagnostics and life sciences in Germany and internationally. The company operates through three segments: Instrumentation, Diatron, and Consumables. The Instrumentation segment designs and manufactures automated analyzer systems for clinical diagnostics and biotechnology customers.